Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics Inc. has demonstrated a robust financial performance with Q3 FY25 revenue reaching $6.8 million, reflecting a 76% year-over-year increase primarily driven by the successful integration of its new model, SCN, which has resulted in accelerated adoption and revenue growth. The company's service revenue more than doubled to $4.6 million, indicating strong demand for its sleep testing and treatment center services, particularly benefiting from the SCN contribution. Furthermore, with an encouraging improvement rate among patients with moderate to severe OSA, coupled with the expected continued deployment of service operations teams, Vivos is positioned for sustained revenue growth moving forward.

Vivos Therapeutics Inc. has experienced a year-over-year revenue decline of 9% in 1H25, largely attributable to its transition towards a new direct sleep center management model, leading to gross margins dropping to 55%. The company faces significant risks that could hinder its sales growth, including increased competition and regulatory challenges, alongside a long history of operating losses, negative cash flow, and a substantial accumulated deficit. Additionally, there are concerns regarding the company's ability to secure capital for expansion and achieve sustainable profitability, which compound the uncertainty surrounding its future financial performance.